Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;461(3):271-82.
doi: 10.1007/s00428-012-1282-3. Epub 2012 Jul 25.

EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas

Shioto Suzuki  1 , Yoh Dobashi, Hiroshi Minato, Ryosuke Tajiri, Tomokazu Yoshizaki, Akishi Ooi
Affiliations

EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas

Shioto Suzuki et al. Virchows Arch. 2012 Sep.

Abstract

Salivary gland carcinomas encompass a wide spectrum of histological entities. To identify candidate therapeutic targets and innovative treatment options for these carcinomas, we examined epidermal growth factor receptor (EGFR), phosphorylated EGFR (p-EGFR), HER2, and phosphorylated forms of Akt (p-Akt) and mammalian target of rapamycin (p-mTOR) in 47 salivary gland tumors using immunohistochemistry. EGFR overexpression was found in 51 % of the tumors (24/47); in particular, EGFR overexpression occurred in mucoepidermoid (seven out of seven) and salivary duct carcinomas (9/12). Although EGFR amplification was not detected by fluorescence in situ hybridization analysis, increased copy number due to polysomy of chromosome 7, which houses EGFR, was observed in 4 of the 24 tumors with EGFR overexpression; this polysomy occurred most frequently in salivary duct carcinomas (three out of nine). HER2 overexpression was observed in 21 % (10/47) of all tumors; in these 10 tumors, HER2 gene amplification was found in seven cases. p-Akt was found in 51 % (24/47) of all tumors, most frequently in mucoepidermoid carcinomas (six out of seven). p-mTOR was found in 57 % of the latter (four out of seven). Consequently, different signaling cascades were found activated: (1) an EGFR/HER2(-Akt)-mTOR-dependent axis, with gene gains of HER2 and/or EGFR, activated in salivary duct carcinoma and carcinoma ex pleomorphic adenoma; (2) an EGFR(-Akt)-mTOR-dependent pathway activated in mucoepidermoid carcinoma or acinic cell carcinoma, without HER2 or EGFR gene alterations; and (3) an Akt-dependent pathway without EGFR/HER2 activation in other types. These findings indicate that phosphoprotein mapping of components in the EGFR/HER2-Akt-mTOR pathways may be a useful guide to select appropriate targeting regimens.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Res. 1994 Nov 1;54(21):5675-82 - PubMed
    1. Br J Cancer. 2009 Feb 24;100(4):623-5 - PubMed
    1. Mod Pathol. 2006 Jul;19(7):986-98 - PubMed
    1. Clin Cancer Res. 2008 Jun 15;14(12):3867-74 - PubMed
    1. Head Neck. 2002 Jul;24(7):632-6 - PubMed

Publication types

MeSH terms

LinkOut - more resources